Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Smarca2 genetic ablation is phenotypically benign in a safety assessment of tamoxifen-inducible conditional knockout rats.

Toxicology and applied pharmacology - 15 Sept 2023

Maher Jonathan, Stagg Nicola, Cain Gary, Andaya Roxanne, Katavolos Paula, Gallardo-Chang Fermin, Pham Anna, Ye Xiaofen, Januario Tom, Alcantar Tuija, Caothien Roger, Roose-Girma Merone, Zhang Donglu, Li Ruina, Chen Shu, Yauch Robert L

Abstract excerpt

SMARCA2 and SMARCA4 are the ATPases of the SWI/SNF chromatin remodeling complex, which play a significant role in regulating transcriptional activity and DNA repair in cells. SMARCA2 has become an appealing synthetic-lethal, therapeutic target in oncology, as mutational loss of SMARCA4 in many cancers leads to a functional dependency on residual SMARCA2 activity. Thus, for therapeutic development, an important...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Triphosphatases
Share to Mice

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms

Share to Tamoxifen

Source

Identifiers

PMID: 37453479
DOI: 10.1016/j.taap.2023.116627

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Smarca2 genetic ablation is phenotypically benign in a safety assessment of tamoxifen-inducible conditional knockout rats.PMID 37453479Read ↗

Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors - a review of patent literature from 2019-30 June 2023.Semantic proximity Read ↗

Renal medullary carcinomas depend upon <i>SMARCB1</i> loss and are sensitive to proteasome inhibitionSemantic proximity Read ↗

Mouse models of SMA: tools for disease characterization and therapeutic developmentSemantic proximity Read ↗

p53 Pathway Inactivation Drives SMARCB1 -deficient p53 -wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 InhibitionSemantic proximity Read ↗

Rats deficient for p53 are susceptible to spontaneous and carcinogen-induced tumorigenesis.Semantic proximity Read ↗

Tumor susceptibility of Rassf1a knockout mice.Semantic proximity Read ↗

Improved generation of rat gene knockouts by target-selected mutagenesis in mismatch repair-deficient animals.Semantic proximity Read ↗

Homozygous and heterozygous p53 knockout rats develop metastasizing sarcomas with high frequency.Semantic proximity Read ↗

Rat somatic genome editing enables ER+ breast cancer modelingSemantic proximity Read ↗

PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers.Semantic proximity Read ↗

The occurrence of intracranial rhabdoid tumours in mice depends on temporal control of Smarcb1 inactivationSemantic proximity Read ↗

Fischer-344 Tp53-knockout rats exhibit a high rate of bone and brain neoplasia with frequent metastasis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.